Document is current

Article History

Received: 28 July 2021

Accepted: 7 February 2022

First Online: 15 March 2022

Declarations

:

: The study was performed in accordance with the Declaration of Helsinki. Institutional ethics approval was required, and patients provided written informed consent.Details of ethics approvals:Princess Alexandra Hospital, Approved 09/12/2008, #2008/148.Greenslopes Private Hospital, Australia, Approved 09/06/2009, #09/23.Cancer Institute NSW, Australia, Approved 28/09/2011, #2011C/06/162.SLHD Ethics Review Committee (RPAH Zone), Royal Prince Alfred Hospital, Australia, Approved 12/07/2013, # X13–0175 and HREC/13/RPAH/261.

: Not applicable.

: Prof Zalcberg serves in an advisory/consultancy role for Merck Serono, Targovax, Merck Sharp & Dohme, Halozyme, Lipotek, Specialized Therapeutics, CEND, Deciphera; owns stock in GW Pharmaceuticals, Aimmune, Vertex, Alnylam, Biomarin, Opthea, Amarin, Concert Pharmaceuticals, Frequency Therapeutics, Global Blood Therapeutics, Gilead, Madrigal Pharmaceuticals, Sangamo Biosciences, Acceleron Pharmaceuticals, Zogenix, Myovant Sciences, Orphazyme, Moderna Therapeutics, and TWST; has received honoraria from Specialised Therapeutics, Merck Serono, Targovax, Halozyme, Gilead Sciences, and Deciphera; and his institution has received research funding from Merck Serono, Bristol-Myers Squibb, AstraZeneca, Pfizer, IQvia, Mylan, Ipsen, Eisai, Medtronic, and MSD Oncology; and has received travel, accommodations, expenses from Merck Serano, AstraZeneca, and Merck Sharp & Dohme.All other authors have no competing interests to declare.